首页> 中文期刊>中国中医眼科杂志 >调脂药在糖尿病视网膜病变治疗中的基础与临床研究进展

调脂药在糖尿病视网膜病变治疗中的基础与临床研究进展

     

摘要

Diabetic retinopathy is closely related to abnormal blood lipid level. Application of lipid-lower-ing agents has played a critical role in protecting the blood-retinal barrier, reducing vascular endothelial cell damage as well as attenuating retinal inflammation and therefore to help control the development of diabetic retinopathy. In management of this disease, extra treat-ment with lipid-lowering agents for patients with diabetic retinopathy whose blood lipid profile was abnormal could better control the progress of diabetic retinopathy and reduce visual damage. In this paper, current progress of exper-imental and clinical researches on treatment of diabetic retinopathy by lipid-lowering agents was reviewed.%糖尿病视网膜病变发生与血脂水平异常有着密切联系.应用调脂药可对血-视网膜屏障起到保护作用,减轻血管内皮细胞损伤,减少视网膜炎症反应,有助于控制糖尿病视网膜病变的发展.在该病的临床治疗过程中,通过检测血脂指标,对于血脂水平异常的糖尿病视网膜病变患者应用调脂药进行辅助治疗,可以更好的控制糖尿病视网膜病变,减少由此造成的视力损伤.本文就调脂药在糖尿病视网膜病变治疗中的基础与临床研究进展进行了综述.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号